Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?

REVIEW

Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?

Francesca Giusti^I; Francesco Tonelli^II; Maria Luisa Brandi^I

^IBone and Mineral Metabolism Unit, Department of Internal Medicine, University Hospital of Careggi, Florence, Italy

^IIDepartment of Clinical Physiopathology, University Hospital of Careggi, Florence, Italy

ABSTRACT

Primary hyperparathyroidism is a common endocrinological disorder. In rare circumstances, it is associated with familial syndromes, such as multiple endocrine neoplasia type 1. This syndrome is caused by a germline mutation in the multiple endocrine neoplasia type 1 gene encoding the tumor-suppressor protein menin. Usually, primary hyperparathyroidism is the initial clinical expression in carriers of multiple endocrine neoplasia type 1 mutations, occurring in more than 90% of patients and appearing at a young age (20-25 years). Multiple endocrine neoplasia type 1/primary hyperparathyroidism is generally accompanied by multiglandular disease, clinically manifesting with hypercalcemia, although it can remain asymptomatic for a long time and consequently not always be recognized early. Surgery is the recommended treatment. The goal of this short review is to discuss the timing of surgery in patients when primary hyperparathyroidism is associated with multiple endocrine neoplasia type 1.

Keywords: Primary hyperparathyroidism; Multiple endocrine neoplasia 1; PHPT-MEN1; Subtotal parathyroidectomy; Total parathyroidectomy.

INTRODUCTION

Primary hyperparathyroidism (PHPT) is a condition caused by hyperfunction of the parathyroid tissue, usually involving only one gland. However, it is often multi-glandular when expressed within complex hereditary syndromes, such as multiple endocrine neoplasia type 1 (MEN1), MEN2A, familial isolated hyperparathyroidism, autosomal dominant mild hyperparathyroidism, neonatal severe hyperparathyroidism, familial hypocalciuric hypercalcemia, and the hyperparathyroidism-jaw tumor syndrome (1,2).

Surgery is the principal treatment for these forms of familial PHPT, apart from in cases associated with familial hypocalciuric hypercalcemia. In this short review, we discuss the timing of surgery in patients with PHPT associated with MEN1.

MEN1 SYNDROME

MEN1 syndrome (MIM#131100) is a rare hereditary cancer syndrome encompassing a variety of more than 20 endocrine and nonendocrine tumors (3). MEN1 is relatively rare (approximately 1 in 30,000) and the definition of MEN1 that is widely used is "a case with tumor in two of the three principal organs: anterior pituitary, parathyroid, and enteropancreatic endocrine tissue" (4,5).

Familial MEN1 is defined as one MEN1 case plus one first-degree relative with one of the three principal tumors or involvement of only one organ and a MEN1 disease-causing germline mutation (6).

The MEN1 gene was identified in 1997 and is the only gene known to be associated with this syndrome (7,8). Genetic testing with direct sequencing of the MEN1 gene is widely available and provides the best method of diagnosis; it can detect MEN1 gene mutations in about 90% of patients with MEN1 within 4-6 weeks. Germline MEN1 mutation is identifiable in 90% of typical MEN1 families and in only 6-10% of isolated cases (9). Some patients without an identified mutation may have large deletions that are not recognized by polymerase chain reaction or have mutations in the tested open reading frame and intron-exon junctions (10,11). Recently it became possible to search for large deletions or duplications in the MEN1 gene using the multiplex ligation-dependent probe amplification assay (12).

Genetic testing makes possible: (a) the identification of asymptomatic adults with a family history of MEN1; (b) the prenatal diagnosis of MEN1; and (c) the elimination of non-carriers by clinical screening (13).

MEN1-PHPT

PHPT in MEN1 is the most common form of endocrinopathy and it represents 2-4% of all forms of PHPT. It is the earliest endocrine expression in most patients, clinically relevant neoplasia is uncommon before puberty, occurring in 90% of MEN1 individuals between 20 and 25 years of age, although mild-to-moderate hyperparathyroidism often emerges during adolescence with mild hypercalcemia. All individuals are affected by 50 years of age (14). Its progression is usually gradual but significant hypercalcemia is occasionally evident in early adolescence.

The signs and symptoms of hypercalcemia include kidney stones, low bone mass, constipation, nausea, vomiting, polyuria, dehydration, hypercalciuria, hypertension, shortened QT interval, lethargy, depression, confusion, and anorexia (14).

The medical therapies of MENl-related PHPT include drugs such as bisphosphonates and calcimimetics. Currently, these drugs have a limited role, being used primarily in the presence of recurrent PHPT or when there are contraindications to surgery (15-17).

The treatment of choice in MEN1-related PHPT is surgery but in this regard some considerations deserve attention.

Age

The age of onset of familial hyperparathyroidism is clearly anticipated at two-three decades compared with the non-syndromic form. The occurrence of hyperparathyroidism at a young age carries a high suspicion of MEN1 syndrome, supported by family history and an association with other endocrinopathies typical of MEN1 syndrome (13). Preclinical diagnosis of MEN1 gene mutations should be offered to all patients with suspected genetic disease (18).

With presymptomatic detection of genetic predisposition to this syndrome, patients can be followed with periodic clinical tumor surveillance for expression of the disease as well as for recurrence after treatment or progression of the disease; knowledge of carrier status enables early intervention (3).

Genotype-phenotype correlation regarding the severity of PHPT in MEN1 cannot be identified (18,19) but knowledge decreases the uncertainty and anxiety in the patient and allows focused surveillance by the physician.

Parathyroid tissue

Generally the PHPT is caused by a multiglandular disease and the parathyroid glands can become hyperplastic or develop adenomas. The growth of the glands is asynchronous and asymmetric (18), as each gland is considered to be a monoclonal lesion in which the germline mutation in the MEN1 gene confers on the parathyroid tissue a high susceptibility for the development of a tumor after the second somatic mutation (2,20).

Morphologically, parathyroid glands in MEN1 may appear macroscopically normal, also because they can differ in terms of volume, weight, and size (18).

Parathyroid adenomas in MEN1 can be ectopic, often located in the thymus, rarely within the thyroid gland, in the anterior mediastinum, in the pericardium, or surrounding the trachea, the esophagus, and the carotid artery (21-23).

Supernumerary glands are frequently found in up to 20% of MEN1 patients, although some authors do not report supernumerary glands (18). A possible explanation for this discrepancy may be the misinterpretation of the size, shape or position of the parathyroid glands in MEN1 (18) because of different surgical strategies used; some of which are more capable of identifying supernumerary glands that would otherwise go unnoticed (24).

Biochemistry and bone mineral density

In young MEN1 patients, PHPT is often asymptomatic; mild ionized hypercalcemia with parathyroid hormone (PTH) within the normal range is typical (25).

However, it should be remembered that PHPT is defined as an excess of PTH with consequent increase in bone turnover, leading to a reversible loss of cortical and trabecular bone caused by an expansion of the remodeling space and a loss of cortical for increased endocortical resorption (26). MEN1 hyperparathyroid patients show more precocious and severe bone loss compared with patients with sporadic PHPT (27-31).

Surgical approaches

The optimal surgical approach in PHPT in MEN1 is still under discussion. The choice being between: subtotal parathyroidectomy with removal of at least three to three and a half glands; and total parathyroidectomy with removal of all parathyroid glands and autologous parathyroid tissue graft.

Subtotal parathyroidectomy requires the identification of all parathyroid glands and the leaving of a remnant the size of a normal parathyroid, approximately 20-30 mg. The dissection must be meticulous to preserve the delicate single end-artery vascular supply to the parathyroid remnant. The parathyroid tissue left in situ should be prepared before resection of the remaining glands, to avoid bleeding and ischemia. Moreover, this residue must be marked with a non-absorbable suture or a surgical clip for future identification. It may be useful to suture the residual remnant gland away from the recurrent laryngeal nerve to facilitate reoperative surgery in case of persistent or recurrent disease (18,32,33).

Total parathyroidectomy provides identification and resection of all four glands followed by a parathyroid heterotopic auto-implant in the non-dominant forearm (2025 pieces, 1 mm each, of fresh parathyroid tissue implanted in one to five pockets created in the brachioradialis muscle). This surgical approach must be accompanied by intraoperative histologic examination, to qualify and confirm the presence of parathyroid tissue in the removed tissues, and by rapid intraoperative PTH evaluation (18,32,33).

Reoperative debulking surgery of the forearm graft for recurrent disease can be performed under local anesthesia.

Prophylactic transcervical thymectomy should be performed in all patients to remove possible intrathymic supernumerary parathyroid glands and prevent the development of thymic carcinoid.

Both procedures should include a meticulous search for ectopic parathyroid tissue, which is commonly encountered within the thymus, mediastinum, carotid sheath, and in the tracheo-esophageal groove (21-23).

Extensive surgery is burdened by an increased risk of permanent hypoparathyroidism (hypocalcemia) and recurrent laryngeal nerve injury. Acute hypoparathyroidism may cause mild to severe neuromuscular symptoms ranging from neuromuscular irritability to seizures. Less extensive surgery yields a higher risk of recurrent disease requiring re-intervention, which increases the risk of more complications. In this latter intervention, multiple operations are often required with a consequent increase in surgical morbidity (18,32,33).

It should be noted that in the hands of an expert surgeon the rate of persistent disease in MENl-associated PHPT is less than 20%, but this may rise to 40-60% for surgeons with less experience. For example, some MEN1 patients may have only a single macroscopically abnormal gland and might undergo inadequate surgery (34).

DISCUSSION

The optimal treatment of PHPT in MEN1 is parathyroidectomy, as it reduces the risk of kidney stones, fractures (improved bone mineral density), and potential cardiovascular morbidity, improving quality of life and reducing gastrin production in MEN1 patients who also have a gastrinoma (35).

Some authors think that parathyroid surgery in patients with MEN1 should be thought of as a debulking or palliative procedure because long-term recurrence is inevitable. Surgery being indicated to treat and prevent the complications of hyperparathyroidism (24).

There are also disputes about surgical timing in patient with MEN1. The surgical indication for PHPT is obvious in patients with symptoms or with severe hypercalcemia; and in these circumstances there appears to be a good risk/ benefit balance. However, if MEN1 syndrome has not been diagnosed preoperatively and if an experienced surgeon is not available, then surgical treatment might not be appropriate (18).

In young patients with asymptomatic, mild hypercalcemia the timing of surgery is controversial, given that recurrence rates increase in relation to the follow-up time.

According to our experience, biochemical screening for hyperparathyroidism is recommended, as well as for the other MEN1-related tumors, and it should be performed regularly in carriers of an MEN1 mutation. This is because clinical manifestation can be mild for long periods of time, but a lack of regular screening may result in the delay of diagnosis and in the development of complications (36).

Total serum calcium concentration corrected for albumin level or ionized calcium fraction was proposed as a single sufficient screening test for hyperparathyroidism in MEN1 (37). However, increased PTH has been observed in MEN1 patients with mild PHPT even in the absence of hypercalcemia, making it necessary to include serum PTH concentration measurement in the screening program (38).

Imaging is not necessary for the diagnosis of parathyroid disease in MEN1 for known multiglandular involvement, but the presence of an experienced MEN1 surgeon is certainly recommended (14).

Assessment of bone mass loss by densitometry is essential in PHPT, mostly in MEN1 patients who have PHPT during the bone mass accretion period (26-31). Lourenco et al. (39) clearly indicated that bone demineralization in MEN1 PHPT patients was early in onset, progressive, frequent, extensive, and severe. Surgery is the most effective way to preserve bone mass in patients with MEN1 PHPT (20).

Therefore, surgery is recommended in young asymptomatic patients in whom the serum calcium values are more than 1 mg/dl over the upper-normal limit and whose bone mineral density values are lower than -2.5 T-score.

Early parathyroidectomy predisposes the patient to an earlier recurrence of hyperparathyroidism and the possibility of progressively challenging reoperations. Late surgical interventions are easier because of the glands' more visible enlargement, but hypercalcemic complications increase.

The diagnosis of MENl-associated PHPT should be confirmed by genetic testing. Carriers of MEN1 mutations require regular screening, regardless of the presence of hyperparathyroidism from the second decade of life, it being difficult to establish a genotype-phenotype relation. When gene carriers are studied prospectively, biochemical evidence of neoplasia can be detected as early as 5-10 years before clinically evident disease, allowing for early surgical intervention and therefore dramatically reducing both the morbidity and the mortality related to the syndrome. Surgery remains the main method of PHPT management in MEN1, despite the high recurrence rate with the need for repeat procedures. Some controversies surround the optimal surgical technique for MEN1 PHPT. The optimal timing for surgery remains controversial and must be assessed case by case without forgetting that the complications of PHPT in MEN1 are early in onset and more severe than in sporadic PHPT. Medical therapy with the goal of bone preservation is an option for patients without symptoms, and calcimimetics effectively normalize calcium levels only with specific indications.

ACKNOWLEDGMENTS

This work was supported by F.I.R.M.O. Fondazione Raffaella Becagli (to MLB).

AUTHOR CONTRIBUTIONS

All the authors were responsible for the manuscript writing.

No potential conflict of interest was reported.

E-mail: [e-mail]

Tel.: [phone]

• 1. Carling T, Udelsman R. Parathyroid tumors. Curr Treat Options Oncol. 2003;4(4):319-28.
• 2. Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002;17(Suppl 2):N37-N43.
• 3. Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T, et al. Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet Med. 2009;11(12):825-35.
• 4. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658-71.
• 5. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol. 2005;17(1):7-12.
• 6. Brandi ML, Bordi C, Tonelli F, Falchetti A, Marx SJ. Multiple endocrine neoplasia type 1. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone Biology. 3. Vol. 2. San Diego, CA, USA: Academic Press; 2008;pp.1345-74.
• 7. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404-7.
• 8. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet. 1997;6(7):1177-83.
• 9. Guo SS, Sawicki MP. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol. 2001;15(10):1653-64.
• 10. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007;92(8):3321-5.
• 11. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103(8):15558-63.
• 12. Pieterman CR, Vriens MR, Dreijerink KM, van der Luijt RB, Valk GD. Care for patients with multiple endocrine neoplasia type 1: the current evidence base. Fam Cancer. 2011;10(1):157-71.
• 13. Falchetti A, Marini F, Giusti F, Cavalli L, Cavalli T, Brandi ML. DNA-based test: when and why to apply it to primary hyperparathyroidism clinical phenotypes. J Intern Med. 2009;266(1):69-83.
• 14. Falchetti A, Marini F, Brandi ML. Multiple endocrine neoplasia type 1. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2005. Available at: http://www.genetests.org.Accessed August 2005
• 15. Falchetti A, Cilotti A, Vaggelli L, Masi L, Amedei A, Cioppi F, et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab. 2008;4(6):351-7.
• 16. Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical use of Cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol. 2010;2010:906163.
• 17. Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, et al. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. Clin Endocrinol (Oxf). 2008;69(5):756-62.
• 18. Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple neoplasia type 1? Ann Surg. 2007;246(6):1075-82.
• 19. Wautot V, Vercherat C, Lespinasse J, Chambe B, Lenoir GM, Zhang CX, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat. 2002;20(1):35-47.
• 20. Carling T. Molecular pathology of parathyroid tumors. Trends Endocrinol Metab. 2001;12(2):53-8.
• 21. Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med. 2005;257(1):27-37.
• 22. Wang CA. The anatomic basis of parathyroid surgery. Ann Surg. 1976;183(3):271-5.
• 23. Akerstrom G, Malmaeus J, Bergstrom R. Surgical anatomy of human parathyroid glands. Surgery. 1984;95:14-21.
• 24. Stalberg P, Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg. 2009;33(11):2234-43.
• 25. Marx SJ. Multiple endocrine neoplasia type 1. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001pp.943-66.
• 26. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008;69(1):1-19.
• 27. Burgess JR, David R, Greenaway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism and response to parathyroidectomy. Arch Surg. 1999;134(10):1119-23.
• 28. Lourenço DMJr, Toledo RA, Mackowiak II, Coutinho FL, Cavalcanti MG, Correia-Deur JE, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features and bone mineral density profile. Eur J Endocrinol. 2008;159(3):259-74.
• 29. Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S, et al. Sporadic and MEN 1 related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009;24(8):1404-10.
• 30. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80(3):723-8.
• 31. Dempster DW, Müller R, Zhou H, Kohler T, Shane E, Parisien M, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007;41(1):19-24.
• 32. Salmeron MD, Gonzalez JM, Sancho Insenser J, Goday A, Perez NM, Zambudio AR, et al. Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1. World J Surg. 2010;34(6):1325-31.
• 33. Schreinemakers JM, Pieterman CR, Scholten A, Vriens MR, Valk GD, Borel Rinkes IH. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg. 2011;35(9):1993-2005.
• 34. Waldmann J, Lopez CL, Langer P, Rothmund M, Bartsch DK. Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. Br J Surg. 2010;97(10):1528-34.
• 35. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008;247(3):501-10.
• 36. Chudek J, Piecha G, Nieszporek T, Marini F, Brandi ML, Wiecek A. Novel 1113delC menin gene mutation in a Polish family with multiple endocrine neoplasia type 1 syndrome. Eur J Intern Med. 2006;17(6):447-9.
• 37. Benson L, Ljunghall S, Akerstrom G, Oberg K. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. Am J Med. 1987;82(4):731-7.
• 38. Hagstrom E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33-9.
• 39. Lourenço DM Jr, Coutinho FL, Toledo RA, Montenegro FL, Correia-Deur JE, Toledo SP. Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J Bone Miner Res. 2010;25(11):2382-91.

Publication Dates

• Publication in this collection
  09 May 2012
• Date of issue
  2012